Here are seven things to know about the cost of treating and curing HCV, according to a consultantlive report.
• Sofosbuvir, manufactured by Gilead Sciences, has been hailed as a breakthrough treatment. A 12-week course of the drug costs approximately $84,000.
• Including the cost of other drugs, such as ribavirin, the cost per treatment of HCV exceeds $150,000.
• Interventions that cost less than $50,000 to $100,000 per quality-adjusted life year saved (QALY) are generally accepted as cost-effective.
• A 48-week regimen of pegylated-interferon plus ribavirin, or a regimen of pegylated-interferon plus ribavirin and adding telaprevir in the case of no virologic response, is considered cost-effective at $27,000 and $37,500 per QALY, respectively.
• Initiating triple therapy with telaprevir plus pegylated-interferon plus ribavirin is not considered cost-effective, at $1.24 million per QALY.
• Adding boceprevir to a of pegylated-interferon plus ribavirin regimen is considered cost-effective at $21,000 to $59,000 per QALY.
• A 24-week regimen of sofosbuvir plus ribavirin cost $17,000 per QALY, while a 12-week regimen of sofosbuvir plus simeprevir cost $11,000 per QALY.
The report concluded that these studies suggest that treating HCV with direct acting agent-based regimens, a newer and more expensive strategy, can be a cost-effective approach.
More articles on gastroenterology:
Dr. Sufiyan Chaudry joins West Tennessee Gastro
How busy are gastroenterologists?
9 gastroenterologists in the news
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.